911,793 Progyny, Inc. $PGNY Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH decreased its position in Progyny, Inc. (NASDAQ:PGNY) by 35.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,636,371 shares of the company’s stock after selling 911,793 shares during the period. Fort Washington Investment Advisors Inc. OH owned approximately 2.13% of Progyny worth $41,220,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new stake in Progyny during the 2nd quarter worth about $29,000. Nykredit A S bought a new position in shares of Progyny in the 2nd quarter worth about $38,000. IFP Advisors Inc lifted its stake in shares of Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after purchasing an additional 1,549 shares during the period. Toth Financial Advisory Corp acquired a new position in shares of Progyny in the 2nd quarter valued at about $65,000. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Progyny in the 2nd quarter valued at about $74,000. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of Progyny stock opened at $27.84 on Thursday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The stock has a 50 day moving average price of $26.48 and a two-hundred day moving average price of $25.37. The stock has a market capitalization of $2.14 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 1.89 and a beta of 1.02.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Research analysts forecast that Progyny, Inc. will post 1.25 EPS for the current year.

Insiders Place Their Bets

In other Progyny news, Director Kevin Gordon sold 11,500 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the sale, the director owned 6,792 shares in the company, valued at approximately $189,768.48. The trade was a 62.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Allison Swartz sold 3,903 shares of the company’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the transaction, the executive vice president owned 75,816 shares in the company, valued at approximately $1,978,797.60. The trade was a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PGNY shares. KeyCorp upped their target price on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Barclays lowered their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 12th. Jefferies Financial Group set a $33.00 price target on Progyny in a research note on Tuesday, September 8th. JPMorgan Chase & Co. boosted their price target on Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, August 21st. Finally, Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.36.

Progyny Company Profile

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.